
C l a i m s

1. Cell permeable iron chelator for use in the treatment of a solid cancer tumour, wherein the compound is N-(1-pyridine-2-yl-methylidene)-N-(*9H*-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine or a pharmaceutically acceptable salt or complex or prodrug thereof of the general formula I, wherein R is H or methyl, $R^1$ is H or $C_1$-$C_4$ alkyl, $R^2$ is H or $C_1$-$C_4$ alkyl.




I

2. The cell permeable iron chelator for use according to claim 1, wherein R is methyl.

3. The cell permeable iron chelator for use according to claim 1, wherein both of R, $R^1$ are methyl.

4. The cell permeable iron chelator for use according to claim 1 or 2, wherein $R^1$ is methyl, in particular 6-methyl or 8-methyl.

5. The cell permeable iron chelator for use according to claim 1, wherein R is methyl, $R^1$ is 8-methyl, and $R^2$ is H.


6. The cell permeable iron chelator for use according to claim 1, wherein

| R is | $R^1$ is | $R^2$ is | |
|---|---|---|---|
| methyl | 8-methyl | H; | or |
| methyl | H | H; | or |
| methyl | 6-methyl | H; | or |
| H | 6-methyl | H; | or, |
| H | 8-methyl | $CH_3$. | |

7. Pharmaceutical composition for use in the treatment of a solid cancer tumour comprising or consisting of the cell permeable iron chelator of any of claims 1 to 6 and a pharmaceutically suitable carrier.

8. Pharmaceutical composition for use according to claim 7, comprising a cancer combating effective dose of said compound.

9. Use of a cell permeable iron chelator in the manufacture of a medicament for the treatment of a solid cancer tumour, wherein the compound is N-(1-pyridine-2-yl-methylidene)-N-(*9H*-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine or a pharmaceutically acceptable salt or complex or prodrug thereof of the general formula I, wherein R is H or methyl, $R^1$ is H or $C_1$-$C_4$ alkyl, $R^2$ is H or $C_1$-$C_4$ alkyl.




I

10. The use according to claim 9, wherein R is methyl.

11. The use according to claim 9, wherein both of R, $R^1$ are methyl.

12. The use according to claim 9 or 10, wherein $R^1$ is methyl, in particular 6-methyl or 8-methyl.

13. The use according to claim 9, wherein R is methyl, $R^1$ is 8-methyl, and $R^2$ is H.

14. The use according to claim 9, wherein

| R is | $R^1$ is | $R^2$ is | |
|---|---|---|---|
| methyl | 8-methyl | H; | or |
| methyl | H | H; | or |
| methyl | 6-methyl | H; | or |

| | | | |
|---|---|---|---|
| H | 6-methyl | H; | or, |
| H | 8-methyl | $CH_3$. | |

15. Use of a pharmaceutical composition comprising or consisting of the cell permeable iron chelator of any of claims 1 to 6 and a pharmaceutically suitable carrier in the manufacture of a medicament for the treatment of a solid cancer tumour.

16. The use according to claim 15, comprising a cancer combating effective dose of said compound.